Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033448097> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3033448097 abstract "BACKGROUND AND PURPOSE: Antiplatelet therapy is associated with decreased ischemic events after neurointerventional procedures. Antiplatelet resistance negates the protective effects of antiplatelet medication, leading to a higher incidence of ischemic events. A possible link between antiplatelet hyper-response and increased hemorrhagic complications has been inadequately investigated. We aimed to examine the correlation between antiplatelet hyper-response and the risk of hemorrhagic complications. MATERIALS AND METHODS: Patients who were treated with antiplatelet medications and underwent neurointerventional procedures were prospectively recruited. We collected the following data: demographics, vascular risk factors, antiplatelet and anticoagulation treatment, antiplatelet responsiveness, coagulation profile, and hemorrhagic complications. P2Y12 receptor–mediated platelet inhibition was tested by using the VerifyNow assay device. The primary end points were postprocedural major and minor hemorrhagic complications. Receiver operator characteristic analysis was used to evaluate the percentage of platelet inhibition as a diagnostic tool for bleeding events. The association between hemorrhage and percentage of platelet inhibition was investigated by using logistic regression modeling. RESULTS: Forty-seven patients were enrolled. The mean age was 56 ± 12 years, and 28% were men. Ten patients (21.3%) developed hemorrhagic complications. Clopidogrel response was higher in patients with a major bleeding complication compared with those with minor or no bleeding (median, 94% versus 24% platelet inhibition; P = .0084). Of the 7 patients (14.9%) defined as hyper-responders with ≥72% platelet inhibition, 42.8% had a major bleeding complication. CONCLUSIONS: Hyper-response to clopidogrel is associated with increased risk of hemorrhagic complications. Larger studies are urgently needed to validate a clinically useful threshold to define clopidogrel hyper-response and to examine the clinical effects of antiplatelet dosage adjustment." @default.
- W3033448097 created "2020-06-12" @default.
- W3033448097 creator A5015105927 @default.
- W3033448097 creator A5018565534 @default.
- W3033448097 creator A5029351300 @default.
- W3033448097 creator A5040854941 @default.
- W3033448097 creator A5068234123 @default.
- W3033448097 date "2013-01-01" @default.
- W3033448097 modified "2023-09-23" @default.
- W3033448097 title "Clopidogrel Hyper-Response and Bleeding Risk in Neurointerventional Procedures" @default.
- W3033448097 hasPublicationYear "2013" @default.
- W3033448097 type Work @default.
- W3033448097 sameAs 3033448097 @default.
- W3033448097 citedByCount "0" @default.
- W3033448097 crossrefType "journal-article" @default.
- W3033448097 hasAuthorship W3033448097A5015105927 @default.
- W3033448097 hasAuthorship W3033448097A5018565534 @default.
- W3033448097 hasAuthorship W3033448097A5029351300 @default.
- W3033448097 hasAuthorship W3033448097A5040854941 @default.
- W3033448097 hasAuthorship W3033448097A5068234123 @default.
- W3033448097 hasConcept C120665830 @default.
- W3033448097 hasConcept C121332964 @default.
- W3033448097 hasConcept C126322002 @default.
- W3033448097 hasConcept C141071460 @default.
- W3033448097 hasConcept C151956035 @default.
- W3033448097 hasConcept C2777628954 @default.
- W3033448097 hasConcept C2777849778 @default.
- W3033448097 hasConcept C2780890252 @default.
- W3033448097 hasConcept C49059817 @default.
- W3033448097 hasConcept C61511704 @default.
- W3033448097 hasConcept C71924100 @default.
- W3033448097 hasConcept C81182388 @default.
- W3033448097 hasConcept C89560881 @default.
- W3033448097 hasConceptScore W3033448097C120665830 @default.
- W3033448097 hasConceptScore W3033448097C121332964 @default.
- W3033448097 hasConceptScore W3033448097C126322002 @default.
- W3033448097 hasConceptScore W3033448097C141071460 @default.
- W3033448097 hasConceptScore W3033448097C151956035 @default.
- W3033448097 hasConceptScore W3033448097C2777628954 @default.
- W3033448097 hasConceptScore W3033448097C2777849778 @default.
- W3033448097 hasConceptScore W3033448097C2780890252 @default.
- W3033448097 hasConceptScore W3033448097C49059817 @default.
- W3033448097 hasConceptScore W3033448097C61511704 @default.
- W3033448097 hasConceptScore W3033448097C71924100 @default.
- W3033448097 hasConceptScore W3033448097C81182388 @default.
- W3033448097 hasConceptScore W3033448097C89560881 @default.
- W3033448097 hasIssue "4" @default.
- W3033448097 hasLocation W30334480971 @default.
- W3033448097 hasOpenAccess W3033448097 @default.
- W3033448097 hasPrimaryLocation W30334480971 @default.
- W3033448097 hasRelatedWork W1189747655 @default.
- W3033448097 hasRelatedWork W1553345686 @default.
- W3033448097 hasRelatedWork W1987779574 @default.
- W3033448097 hasRelatedWork W2009986485 @default.
- W3033448097 hasRelatedWork W2016028915 @default.
- W3033448097 hasRelatedWork W2101924617 @default.
- W3033448097 hasRelatedWork W2115214159 @default.
- W3033448097 hasRelatedWork W2268174402 @default.
- W3033448097 hasRelatedWork W2326823114 @default.
- W3033448097 hasRelatedWork W2331278286 @default.
- W3033448097 hasRelatedWork W2332514885 @default.
- W3033448097 hasRelatedWork W2375272954 @default.
- W3033448097 hasRelatedWork W2539069047 @default.
- W3033448097 hasRelatedWork W2561539584 @default.
- W3033448097 hasRelatedWork W2607741594 @default.
- W3033448097 hasRelatedWork W2889582985 @default.
- W3033448097 hasRelatedWork W2980720515 @default.
- W3033448097 hasRelatedWork W3048061055 @default.
- W3033448097 hasRelatedWork W3082109096 @default.
- W3033448097 hasRelatedWork W1889761305 @default.
- W3033448097 hasVolume "34" @default.
- W3033448097 isParatext "false" @default.
- W3033448097 isRetracted "false" @default.
- W3033448097 magId "3033448097" @default.
- W3033448097 workType "article" @default.